Polysaccharide-Based Chiral Chromatography Media in HPLC and SFC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Polysaccharide-Based Chiral Chromatography Media in HPLC and SFC
Polysaccharide-based chiral stationary phases have been developed that comprise chiral selectors immobilized on their support rather than being physically coated. These materials are completely solvent stable, thereby increasing selectivity and and enabling the development of new chiral selectors that have been too unstable in a coated form for general use.


Pharmaceutical Technology



Figure 2: Separation of the enantiomers of prilocaine. Green is Chiralpak IA, blue is Chiralpak IB, and red is Chiralpak IC. Mobile phase is hexane–2-propanol 8:2; flow rate = 1 mL/min; column dimensions = 250 × 4.6 mm.
Immobilizing otherwise unstable chiral selectors has great advantages, including the ability to separate enantiomers that cannot be resolved on existing CSPs. The unique structure of Chiralpak IC often allows separations of different selectivity from other polysaccharide-based CSPs. A combination of Chiralpak IC with Chiralpak IA and IB is replacing the older generation coated phases. The three immobilized columns are complementary, and a separation can sometimes be found on only one column. Figure 2 shows the example of prilocaine where the enantiomers are poorly separated with Chiralpak IA and IB but are well resolved with Chiralpak IC (8).


Figure 3: Separation of indoprofen enantiomers. Column was Chiralpak IC, 250 × 4.6 mm. All mobile phases contained 0.1% trifluoroacetic acid. Flow rate = 1 mL/min. Green is 30% ethanol in hexane; blue is 35% 2-propanol in hexane; and red is 2% methanol in dichloromethane.
Immobilization of the chiral polymer increases solvent stability, which allows modification of the selectivity of chiral separations by the modulation of the solvent composition and its components. Figure 3 shows the exploitation of the mobile-phase constituents. Neither of the conventional mobile phases (hexane–2-propanol or hexane–ethanol) gave good resolution of the enantiomers of indoprofen using Chiralpak IC (8). Dichloromethane-based mobile phase improved separation in a significantly shorter time.

Separation method development

The restrictions on solvents that applied to the early generation of coated polysaccharide CSPs made the development of separation methods using them relatively straightforward. One screened with four mobile phase mixtures—hexane:ethanol, hexane:2-propanol, acetonitrile, and 1:1 ethanol:methanol. Following this, the optimization also was simple because there were either "hits" or not, and the opportunity for modifying the separations achieved were limited. This limitation is an important advantage of these CSPs because the vast majority of separations can be found using these four solvents and only four CSPs—the tris-(3,5-dimethylphenylcarbamate) of cellulose and of amylose, cellulose tris(4-methylbenzoate), and amylose tris(S)-α-methylbenzylcarbamate.

Using immobilized CSPs removes the restrictions of solvents to the extent where any organic solvent with a reasonable viscosity is now accessible. This is a tremendous advantage in that it allows optimization of separations using solvent selectivity effects not available for methods using the coated CSPs. Nonetheless, this also may complicate the development of separation methods simply because of the bewildering array of solvents from which to choose.

To simplify the task, statistical studies have been conducted to assist in solvent selection and reduce the number that should be tried to a reasonable few while retaining maximum resolution and selectivity. Of course, such statistical guidelines must be based upon a wide range of applications to ensure their relevance, and there will always be some exceptions.

Two main sets of data, each based on the separation of a different set of 70 compounds, have been developed. Each set was screened using a wide range of solvents, and the success rates arising from each were determined.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here